Prakash Upreti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prakash Upreti has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Chadi Alraies
Detroit Medical Center Detroit Michigan USA
5 shared publications - Mohammad Hamza
Department of Internal Medicine, Albany Medical Center, Albany, NY 12208, USA
4 shared publications - Yasemin Bahar
Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, USA
3 shared publications - Junaid Mir
University of Missouri, Columbia, USA
2 shared publications - Kripa Rajak
Department of Internal Medicine, UPMC Harrisburg, Pennsylvania
2 shared publications - Mobeen Zaka Haider
Division of Cardiology, West Virginia University, Morgantown, WV 26506, USA
2 shared publications
Latest Publications
- 17 April 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (6) , 1-14
Optical coherence tomography versus angiography guided percutaneous coronary intervention: a systematic review and meta-analysis
- 17 April 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (6) , 1-14
Optical coherence tomography versus angiography guided percutaneous coronary intervention: a systematic review and meta-analysis
- 30 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Impella in Cardiogenic Shock: An Updated Meta-Analysis
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
- 30 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Impella in Cardiogenic Shock: An Updated Meta-Analysis
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
- 9 October 2025
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 25 (1) , e0406
Medical Management Versus PCI in Patients with Stable Angina: An Updated Systematic Review and Meta-analysis
Background: Despite the clinical guidelines favoring medical therapy for stable angina, the optimal management of these patients remains unclear. Here, we compare medical management (MM) versus percutaneous coronary intervention (PCI) in patients with stable angina. Methods: An extensive literature search was conducted using PubMed and Embase to identify randomized controlled trials of interest. Data were extracted and analyzed using a random-effects model to calculate pooled odds ratios (OR). Results: Our meta-analysis of 28 randomized controlled trials included 9346 PCI patients and 9503 medically managed patients. The mean age was 62.5 ± 7.6 years in the PCI group and 62.8 ± 7.4 years in the other group. Men comprised 68% and 70% of the PCI and MM groups, respectively. Over a mean follow-up of 2.64 years, PCI was associated with a significantly lower incidence of myocardial infarction compared with MM (OR, 0.84; 95% CI, 0.74–0.96; P = 0.01). Although PCI showed trends toward lower odds of unplanned revascularizations and major adverse cardiovascular (CV) events, these differences were not statistically significant. There were no differences in outcomes of freedom from angina, unstable angina, nonfatal myocardial infarction, stroke, all-cause mortality, or CV death. Conclusion: Advances in CV imaging and catheterization techniques have improved risk stratification and outcomes of PCI in stable angina. Further research is needed to identify clinical subgroups that benefit most from each treatment modality.
- 9 October 2025
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 25 (1) , e0406
Medical Management Versus PCI in Patients with Stable Angina: An Updated Systematic Review and Meta-analysis
Background: Despite the clinical guidelines favoring medical therapy for stable angina, the optimal management of these patients remains unclear. Here, we compare medical management (MM) versus percutaneous coronary intervention (PCI) in patients with stable angina. Methods: An extensive literature search was conducted using PubMed and Embase to identify randomized controlled trials of interest. Data were extracted and analyzed using a random-effects model to calculate pooled odds ratios (OR). Results: Our meta-analysis of 28 randomized controlled trials included 9346 PCI patients and 9503 medically managed patients. The mean age was 62.5 ± 7.6 years in the PCI group and 62.8 ± 7.4 years in the other group. Men comprised 68% and 70% of the PCI and MM groups, respectively. Over a mean follow-up of 2.64 years, PCI was associated with a significantly lower incidence of myocardial infarction compared with MM (OR, 0.84; 95% CI, 0.74–0.96; P = 0.01). Although PCI showed trends toward lower odds of unplanned revascularizations and major adverse cardiovascular (CV) events, these differences were not statistically significant. There were no differences in outcomes of freedom from angina, unstable angina, nonfatal myocardial infarction, stroke, all-cause mortality, or CV death. Conclusion: Advances in CV imaging and catheterization techniques have improved risk stratification and outcomes of PCI in stable angina. Further research is needed to identify clinical subgroups that benefit most from each treatment modality.
- 18 July 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 229, 22-27
Meta-Analysis Comparing Drug-Coated Balloon Versus Plain Old Balloon Angioplasty for In-Stent Restenosis of Coronary Arteries
- 18 July 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 229, 22-27
Meta-Analysis Comparing Drug-Coated Balloon Versus Plain Old Balloon Angioplasty for In-Stent Restenosis of Coronary Arteries
- Open Access
- 16 April 2023
- Published by Springer Nature in Cureus
- Vol. 15 (4)
Exploring the Causal Relationship Between Arterial and Venous Thromboembolism: A Case Series With Review of Literature
Venous thromboembolism (VTE) occurs due to venous stasis or low flow state within the blood vessels, resulting in subsequent fibrin and platelet aggregation leading to thrombosis. Arterial thrombosis affects various arteries including coronaries and is primarily due to platelet aggregation with little fibrin deposition leading to thrombosis. Although both arterial and venous thrombosis are considered as separate entities, some studies have suggested an association between them despite having distinctive causative factors. We retrospectively reviewed patients at our institution who were admitted with acute coronary syndrome (ACS) and underwent cardiac catheterization over a decade between 2009 and 2020 to look for patients who had both venous thromboembolic events and ACS. Here, we report a case series of three such patients who were found to have both VTE and coronary arterial thrombosis. However, it is unclear if having one of venous vs arterial clot increases the risk of having other vascular conditions, and further studies are needed to evaluate this hypothesis in the near future.
- 16 April 2023
- Published by Springer Nature in Cureus
- Vol. 15 (4)
Open AccessExploring the Causal Relationship Between Arterial and Venous Thromboembolism: A Case Series With Review of Literature
Venous thromboembolism (VTE) occurs due to venous stasis or low flow state within the blood vessels, resulting in subsequent fibrin and platelet aggregation leading to thrombosis. Arterial thrombosis affects various arteries including coronaries and is primarily due to platelet aggregation with little fibrin deposition leading to thrombosis. Although both arterial and venous thrombosis are considered as separate entities, some studies have suggested an association between them despite having distinctive causative factors. We retrospectively reviewed patients at our institution who were admitted with acute coronary syndrome (ACS) and underwent cardiac catheterization over a decade between 2009 and 2020 to look for patients who had both venous thromboembolic events and ACS. Here, we report a case series of three such patients who were found to have both VTE and coronary arterial thrombosis. However, it is unclear if having one of venous vs arterial clot increases the risk of having other vascular conditions, and further studies are needed to evaluate this hypothesis in the near future.